Latest Breaking News On - Greg salsburg - Page 3 : comparemela.com

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with.

United statesCitius pharmaIlanit allenGreg salsburgLeonard mazurUniversity of texas md anderson cancer centerCompany nasdaqCitius pharmaceuticals incSecurities exchangeExchange commissionData monitoring committeeInfectious diseases society of americaCitius pharmaceuticalsChief executive officerIndependent data monitoring committeeLok phase

Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Citius pharmaLeonard mazurGreg salsburgMyron czuczmanIlanit allenExchange commissionCompany nasdaqUniversity of pittsburghCitius pharmaceuticals incUniversity of minnesotaPrnewswire citius pharmaceuticals incSecurities exchangeHillman cancer centerUniversity of pittsburgh medical centerMasonic cancer centerChief medical officer

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post.

United statesNew yorkNew jerseyJaime bartushakIlanit allenTaylor zhangMyron holubiakCitius pharmaGreg salsburgMyron czuczmanLeonard mazurDrug administrationSecurities exchangeWyrick robbins yates pontonExchange commissionMaxim group

Citius Pharmaceuticals, Inc Receives Regulatory Guidance from the U S Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance.

Greg salsburgIlanit allenLeonard mazurDrug administrationPrnewswire citius pharmaceuticals incCompany nasdaqExchange commissionSecurities exchangeCitius pharmaceuticals incCompany biologics license applicationBiologics license applicationCitius pharmaceuticalsFast trackSecurities actSecurities exchange actAnnual report

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

New jerseyUnited statesLeonard mazurIlanit allenGreg salsburgCitius pharmaceuticals incPrnewswire citius pharmaceuticals incCompany nasdaqSecurities exchangeExchange commissionJersey technology business tax certificate transfer programDevelopment rd expensesChief executive officerHalo lido phaseCitius pharmaceuticalsFast track